CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net income (loss)	$ (440,242)	$ (1,131,156)	$ (852,824)
Non-cash adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	54,054	44,468	47,567
Amortization and interest accretion related to operating leases	42,977	41,082	42,127
Non-cash interest expense on liability related to the sale of future royalties	106,554	104,200	116,562
Stock-based compensation	221,680	230,649	165,717
Realized and unrealized loss (gain) on marketable equity securities	16,944	33,312	(55,695)
Loss on extinguishment of debt	0	76,586	0
Change in fair value of development derivative liability	90,997	94,659	38,433
Other	433	479	19,243
Changes in operating assets and liabilities:
Accounts receivable, net	(87,939)	(45,597)	(101,799)
Inventory	18,367	(34,136)	(26,415)
Prepaid expenses and other assets	(9,029)	(38,507)	(32,093)
Accounts payable, accrued expenses and other liabilities	80,840	191,769	88,240
Operating lease liability	(46,502)	(43,171)	(40,352)
Deferred revenue	55,022	(65,911)	(50,404)
Net cash provided by (used in) operating activities	104,156	(541,274)	(641,693)
Cash flows from investing activities:
Purchases of property, plant and equipment	(62,211)	(72,059)	(76,372)
Purchases of marketable securities	(1,823,501)	(1,976,961)	(1,656,114)
Sales and maturities of marketable securities	1,553,800	2,231,568	1,463,550
Proceeds from maturity of restricted investments	58,475	89,951	41,975
Purchases of restricted investments	(58,475)	(98,451)	(42,141)
Other investing activities	(4,438)	(4,694)	(4,198)
Net cash (used in) provided by investing activities	(336,350)	169,354	(273,300)
Cash flows from financing activities:
Proceeds from exercise of stock options and other types of equity, net	147,464	259,360	246,268
Proceeds from convertible debt, net	0	1,016,111	0
Purchases of capped calls related to convertible debt	0	(118,611)	0
Proceeds from the sale of future royalties	0	0	500,000
Proceeds from development derivative	24,667	31,000	19,600
(Repayment of) proceeds from term loan facility	0	(762,107)	500,000
Other financing activities	0	0	(18,750)
Net cash provided by financing activities	172,131	425,753	1,247,118
Effect of exchange rate changes on cash, cash equivalents and restricted cash	6,391	(7,430)	(9,018)
Net (decrease) increase in cash, cash equivalents and restricted cash	(53,672)	46,403	323,107
Cash, cash equivalents and restricted cash, beginning of period	868,556	822,153	499,046
Cash, cash equivalents and restricted cash, end of period	814,884	868,556	822,153
Supplemental disclosure of cash flows:
Cash paid for interest	32,118	45,235	24,657
Supplemental disclosure of noncash investing activities:
Capital expenditures included in accounts payable and accrued expenses	$ 3,805	$ 5,213	$ 13,599